These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2628237)

  • 1. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
    Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
    Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
    Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisantrene in relapsed and refractory acute myelogenous leukemia.
    Spadea A; Petti MC; Aloespiriti MA; Avvisati G; De Gregoris C; Fazi P; Latagliata R; Amadori S; Mandelli F
    Leuk Lymphoma; 1993 Feb; 9(3):217-20. PubMed ID: 8471980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
    Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
    Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
    Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
    Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
    Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
    Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
    Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.
    Visani G; Rizzi S; Tosi P; Cenacchi A; Gamberi B; Lemoli RM; Papadopulu P; Tura S
    Haematologica; 1990; 75(6):527-31. PubMed ID: 2098293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
    Vogler WR; Trulock PD
    Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisantrene, an active drug in patients with advanced breast cancer.
    Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
    Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
    Myers JW; Von Hoff DD; Clark GM; Coltman CA
    Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
    [No Abstract]   [Full Text] [Related]  

  • 17. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of bisantrene in acute nonlymphoblastic leukemia.
    Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M
    Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
    Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amsacrine in refractory acute leukemia.
    Griffin JD; Maguire ME; Mayer RJ
    Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.